Analyst RecommendationAnalyst recommendation for Compass Therapeutics is OUTPERFORM based on its promising pipeline and market opportunities.
Clinical Trial SuccessCompass Therapeutics announced positive topline results on the primary efficacy endpoint for COMPANION-002, the company's ongoing Phase 2/3 randomized study of tovecimig in combination with paclitaxel in patients with advanced BTC.
Market PotentialSEER data suggests approximately 23,000 annual US patients, a figure supported by AZN and independent parties, indicating a larger than expected market size for BTC.